Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumithra J Mandrekar

Showing results (31-40 of 157) with videos related to

Pageof 16
Sort By:
Statistics in Medicine|October 4, 2006
An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinationsSumithra J Mandrekar, Yue Cui, Daniel J Sargent
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 1, 2021
Statistical Models in Clinical StudiesShigeyuki Matsui, Jennifer Le-Rademacher, Sumithra J Mandrekar
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2012
A 2-stage phase II design with direct assignment option in stage II for initial marker validationMing-Wen An, Sumithra J Mandrekar, Daniel J Sargent
Chinese Clinical Oncology|September 27, 2015
Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trialsRyan S Alden, Sumithra J Mandrekar, Geoffrey R Oxnard
Cancer Letters|March 19, 2016
Precision oncology: A new era of cancer clinical trialsLindsay A Renfro, Ming-Wen An, Sumithra J Mandrekar
The New England Journal of Medicine|April 25, 2019
Ibrutinib Regimens in Older Patients with Untreated CLL. ReplyJennifer A Woyach, Amy S Ruppert, Sumithra J Mandrekar
Statistical Methods in Medical Research|April 30, 2026
PRO-ADD: Patient-empowered dose-finding trials integrating safety, preliminary efficacy and patient-reported outcomes for optimal dose selectionEmily Alger, Sumithra J Mandrekar, Jun Yin, et al.
Statistics in Medicine|November 9, 2004
Statistical modelling of the differences between successive R-R intervalsSumithra J Mandrekar, Haikady N Nagaraja, Gary G Berntson
Contemporary Clinical Trials|May 14, 2013
A review of phase II trial designs for initial marker validationSumithra J Mandrekar, Ming-Wen An, Daniel J Sargent
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2020
Introducing the Journal of Thoracic Oncology Statistical SeriesSumithra J Mandrekar, Jennifer Le-Rademacher, Alex A Adjei
Pageof 16

Showing results (31-40 of 157) with videos related to

Sort By:
Pageof 16
Statistics in Medicine|October 4, 2006
An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinationsSumithra J Mandrekar, Yue Cui, Daniel J Sargent
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 1, 2021
Statistical Models in Clinical StudiesShigeyuki Matsui, Jennifer Le-Rademacher, Sumithra J Mandrekar
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2012
A 2-stage phase II design with direct assignment option in stage II for initial marker validationMing-Wen An, Sumithra J Mandrekar, Daniel J Sargent
Chinese Clinical Oncology|September 27, 2015
Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trialsRyan S Alden, Sumithra J Mandrekar, Geoffrey R Oxnard
Cancer Letters|March 19, 2016
Precision oncology: A new era of cancer clinical trialsLindsay A Renfro, Ming-Wen An, Sumithra J Mandrekar
The New England Journal of Medicine|April 25, 2019
Ibrutinib Regimens in Older Patients with Untreated CLL. ReplyJennifer A Woyach, Amy S Ruppert, Sumithra J Mandrekar
Statistical Methods in Medical Research|April 30, 2026
PRO-ADD: Patient-empowered dose-finding trials integrating safety, preliminary efficacy and patient-reported outcomes for optimal dose selectionEmily Alger, Sumithra J Mandrekar, Jun Yin, et al.
Statistics in Medicine|November 9, 2004
Statistical modelling of the differences between successive R-R intervalsSumithra J Mandrekar, Haikady N Nagaraja, Gary G Berntson
Contemporary Clinical Trials|May 14, 2013
A review of phase II trial designs for initial marker validationSumithra J Mandrekar, Ming-Wen An, Daniel J Sargent
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2020
Introducing the Journal of Thoracic Oncology Statistical SeriesSumithra J Mandrekar, Jennifer Le-Rademacher, Alex A Adjei
Pageof 16